Inhibitors of Erks and p38 signaling pathways are in many clinical trials dedicated to treating different types of cancer, inflammation, pain, rheumatoid arthritis, asthma, and neurodegenerative diseases, including Alzheimer’s [35,36]. Here, MAPK1 is linked to asthma.